News

MedCity News6d
Ouster of Peter Marks & Mass FDA Layoffs Have Biotech Sector Bracing for Regulatory Disruptions
As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and ...
Fierce Pharma6d
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Labiotech.eu6d
Top biotech deals of March 2025
Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...